Abstract
Objective: This study aims to screen the aptamers of LGR5 through MARAS platform to regulate the migration, proliferation, and invasion in breast cancer cells. Methods: MARAS platform was used to screen adaptation of LGR5. The expressions of LGR5, β-catenin, c-Myc, Cyclin D1 and DKK1 were detected by RT-qPCR and Western blot. Cell viability was analyzed by MTT assay. The capacity of tumor cell migration and invasion were evaluated using wound healing and transwell assays. Results: Anti-LGR5-APtamer was obtained by screening on MARAS platform. Anti-LGR5-aptamer can remarkably inhibit MDA-MB-231 cells growth, such as proliferation, migration and invasion Mechanically, anti-LGR5-aptamer inhibits β-catenin, C-MyC, Cyclin D1 expression and promotes the expression of DKK1. In addition, the Dox-anti-LGR5-aptamer system can enhance the ability of Dox to enter MDA-MB-231 cells, enabling them to exert tumor suppressive function. Conclusions: Screening of LGR5 aptamers through MARAS platform can effectively inhibit the function of LGR5 in breast cancer cells. In addition, using LGR5 aptamers as biological probes loaded with chemotherapy drugs may provide a future strategy for thereapy of breast cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
